Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;4(2):77-83.
doi: 10.1177/1756287212437361.

Optimizing the management of benign prostatic hyperplasia

Dean S Elterman, Jack Barkin, Steven A Kaplan

Optimizing the management of benign prostatic hyperplasia

Dean S Elterman et al. Ther Adv Urol. 2012 Apr.

Abstract

One of the challenges facing primary care physicians and specialists as the population ages is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). While as many as 18% of men in their 40s report bother from an enlarged prostate, that figure rises dramatically, whereby 50% of men in their 50s and 90% of men in their 90s will complain of bothersome symptoms related to an enlarged prostate. Studies have shown that BPH is a progressive disease, which if left untreated can result in worsening of symptoms, acute urinary retention and renal failure. Until about 20 years ago the only management option available to urologists was surgery. In the early 1990s medical therapy emerged as the predominant treatment for BPH. Therapy may be tailored to target symptoms and progression of disease.

Keywords: 5-alpha-reducinhibitors; LUTS; alpha-blockers; anticholinergics; benign prostatic hyperplasia.

PubMed Disclaimer

Conflict of interest statement

Dr Barkin has been a clinical investigator, speaker and sits on the medical advisory board for Pfizer, Lilly, Merck, GSK, Neotract.

References

    1. Abrams P., Chapple C., Khoury S., Roehrborn C., De la Rosette J. (2009) Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 181: 1779–1787 - PubMed
    1. Abrams P., Kaplan S., De Koning Gans H.J., Millard R. (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004; discussion 1004 - PubMed
    1. Andersson K.E. (2011) Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 59: 377–386 - PubMed
    1. Barkin J. (2011a) Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 18(Suppl.): 14–19 - PubMed
    1. Barkin J. (2011b) Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence 5: 483–490 - PMC - PubMed

LinkOut - more resources